November 17, 2016 - By Hazel Jackson · 0 Comments
The stock of Teligent Incorporated (NASDAQ:TLGT) registered a decrease of 2.1% in short interest. TLGT’s total short interest was 8.42M shares in November as published by FINRA. Its down 2.1% from 8.60M shares, reported previously. With 143,600 shares average volume, it will take short sellers 59 days to cover their TLGT’s short positions. The short interest to Teligent Incorporated’s float is 19.62%. About 101,614 shares traded hands. Teligent Inc (NASDAQ:TLGT) has risen 30.27% since April 15, 2016 and is uptrending. It has outperformed by 25.64% the S&P500.
Teligent, Inc., formerly IGI Laboratories, Inc., is a specialty generic pharmaceutical company. The company has a market cap of $379.37 million. The Firm markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It currently has negative earnings. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter and cosmetic industries.
Teligent, Inc., formerly IGI Laboratories, Inc., incorporated on August 26, 1977, is a specialty generic pharmaceutical company. Under its own label, the Company markets and sells generic injectable pharmaceutical products in the United States and Canada. It is also marketing over eight generic topical pharmaceutical products and approximately four branded generic pharmaceutical products. The Firm provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. The Firm focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its current contract manufacturing and formulation services business. The Company’s pipeline includes over 30 Abbreviated New Drug Applications (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products. In addition, it has over four abbreviated new drug submissions (ANDS), on file with Health Canada. It holds additional over 40 product candidates at various stages of its development pipeline, approximately 10 of which are on stability testing.
More notable recent Teligent Inc (NASDAQ:TLGT) news were published by: Marketwatch.com which released: “Teligent Inc. NASDAQ: TLGT” on October 29, 2015, also Prnewswire.com with their article: “Teligent, Inc. Announces Third Quarter 2016 Results” published on October 27, 2016, Prnewswire.com published: “Teligent, Inc. Announces The Opening Of A Product Development Laboratory In …” on October 11, 2016. More interesting news about Teligent Inc (NASDAQ:TLGT) were released by: Prnewswire.com and their article: “Teligent, Inc. To Hold Conference Call For 3rd Quarter 2016 Results” published on October 14, 2016 as well as Prnewswire.com‘s news article titled: “Teligent, Inc. To Present At 7th Annual Craig-Hallum Alpha Select Conference …” with publication date: November 16, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Hazel Jackson